Mannkind, Game-Chancer in Sachen Diabetik? (Seite 351)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 1
Gesamt: 593.804
Gesamt: 593.804
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,1800
USD
-0,24 %
-0,0100 USD
Letzter Kurs 17:23:56 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 | |
| 6,9300 | +17,46 | |
| 0,6125 | +13,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5050 | -15,83 | |
| 6,6300 | -16,71 | |
| 3,1100 | -18,10 | |
| 0,5834 | -21,16 | |
| 1,9500 | -25,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
- during Q&A a women read a statement about SEC investment including insider trading violation and Matt answered stating company is aware of short sales investigation, but never heard anything about insider trading violations.
- Mat asked if company has a final termination agreement including compensation for Sanofi sabotaged launch and he said they have a termination agreement getting Afrezza back, but could not discuss any monetary arrangements/discussion/strategies and said say tune.
- Michael Castaglia presented a very thorough commercial strategy that will build on what Sanofi did not do, did wrong and would target healthcare provider education, Endo's and an easier/faster patient 1st time user experience for Afrezza. He is introducing the low cost Spirometry to healthcare providers and a 24/7 Afrezza Service Line, whereby, doctors and patients can get prior authorization done and patients filing their 1st prescriptions a quickly as 72 hours.
- Q&A someone brought up an interesting suggestion Mannkind should use Pfizer Insulin to make Afrezza available outside the U.S. in 3rd world countries with the help of the Gates Foundation, not so much to make money, but to get Afrezza used globally to demonstrate its paradigm changing benefits.
- tour of the manufacturing plant was truly impressive and its a state of the art facility.What Mannkind is doing in Danbury is unmatched in the industry and likely cannot be matched exactly by big pharma. Generic competition will be very difficult and it will keep Mannkind protected long after patent expiration.
- shareholders at the meeting blaming Sanofi for Afrezza failed launch.
Quelle: Yahoo Board!
- Mat asked if company has a final termination agreement including compensation for Sanofi sabotaged launch and he said they have a termination agreement getting Afrezza back, but could not discuss any monetary arrangements/discussion/strategies and said say tune.
- Michael Castaglia presented a very thorough commercial strategy that will build on what Sanofi did not do, did wrong and would target healthcare provider education, Endo's and an easier/faster patient 1st time user experience for Afrezza. He is introducing the low cost Spirometry to healthcare providers and a 24/7 Afrezza Service Line, whereby, doctors and patients can get prior authorization done and patients filing their 1st prescriptions a quickly as 72 hours.
- Q&A someone brought up an interesting suggestion Mannkind should use Pfizer Insulin to make Afrezza available outside the U.S. in 3rd world countries with the help of the Gates Foundation, not so much to make money, but to get Afrezza used globally to demonstrate its paradigm changing benefits.
- tour of the manufacturing plant was truly impressive and its a state of the art facility.What Mannkind is doing in Danbury is unmatched in the industry and likely cannot be matched exactly by big pharma. Generic competition will be very difficult and it will keep Mannkind protected long after patent expiration.
- shareholders at the meeting blaming Sanofi for Afrezza failed launch.
Quelle: Yahoo Board!
Castagna hat auf folgendes auf Twitter geschrieben:
Thank you AstraZeneca for letting go of some great people with diabetes experience this week!
https://twitter.com/castagna2011
Thank you AstraZeneca for letting go of some great people with diabetes experience this week!
https://twitter.com/castagna2011
Sharholder Meeting Highlights Michael Castaglia Presentation & Chinese Investment Group Offering To Make Equity Investment In Mannkin
.
Overall the meeting was very positive and I would say Michael Castaglia's presentation on the company's commercial strategy was one of the highlights. The guy knows his stuff and he was very impressive & articulate explaining his strategy. Mannkind is very lucky to have hired him. Shareholders who were in attendance seemed for the most part to be supportive of Mannkind's 2.0 strategy. The one highlight in the meeting that caught me by complete surprise was during the Q&A session when a gentleman stood up identifying himself as a friend & former business partner of Alfred Mann having served on a Board of Directors with Al for an Aerospace Company and he also identified himself as a current member of Chinese Investment Group and he went on to make a very public offer to Mannkind at the meeting that his investment firm wants to make a sizable investment in Mannkind and would like to speak to Mannkind. Matt Pfeffer seemed taken back by the statement and did not respond except to say the gentleman really did not ask a question. It will be interesting to see if this goes anywhere or if it gets pick up by the media about Mannkind getting a public investment offer at the meeting. Here is some highlights surrounding the meeting.
- all agenda items voted on were approved by shareholders
- Mannkind's Chairman started off the meeting and handled official voting segment.
- Matt Pfeffer spoke but did not offer anything new
- Michael Castaglia was the only other member of management to speak at the meet and he was great
- small convenient spirometry device costing $350 to be promoted was shown at the meeting
- new sample pack was was shown at the meeting
- Mannkind will have a big presence at ADA Meeting
- clamp studies completed will be used for label updates
- industry layoff benefiting Mannkind hiring & Astra reps likely to shift onto Afrezza
- DTC marketing will be done locally targeting community sponsorship events.
- Tribute to Alfred Mann & unveiled statue of Al
Quelle: Yahoo Board!
.
Overall the meeting was very positive and I would say Michael Castaglia's presentation on the company's commercial strategy was one of the highlights. The guy knows his stuff and he was very impressive & articulate explaining his strategy. Mannkind is very lucky to have hired him. Shareholders who were in attendance seemed for the most part to be supportive of Mannkind's 2.0 strategy. The one highlight in the meeting that caught me by complete surprise was during the Q&A session when a gentleman stood up identifying himself as a friend & former business partner of Alfred Mann having served on a Board of Directors with Al for an Aerospace Company and he also identified himself as a current member of Chinese Investment Group and he went on to make a very public offer to Mannkind at the meeting that his investment firm wants to make a sizable investment in Mannkind and would like to speak to Mannkind. Matt Pfeffer seemed taken back by the statement and did not respond except to say the gentleman really did not ask a question. It will be interesting to see if this goes anywhere or if it gets pick up by the media about Mannkind getting a public investment offer at the meeting. Here is some highlights surrounding the meeting.
- all agenda items voted on were approved by shareholders
- Mannkind's Chairman started off the meeting and handled official voting segment.
- Matt Pfeffer spoke but did not offer anything new
- Michael Castaglia was the only other member of management to speak at the meet and he was great
- small convenient spirometry device costing $350 to be promoted was shown at the meeting
- new sample pack was was shown at the meeting
- Mannkind will have a big presence at ADA Meeting
- clamp studies completed will be used for label updates
- industry layoff benefiting Mannkind hiring & Astra reps likely to shift onto Afrezza
- DTC marketing will be done locally targeting community sponsorship events.
- Tribute to Alfred Mann & unveiled statue of Al
Quelle: Yahoo Board!
Al Castagn, der medical chief von Mannkind hat folgenden Tweet gesandt:
A Team is in place! Thank you to everyone who accepted offers this week. One last opening let's see who the lucky person will be! #winning!
A Team is in place! Thank you to everyone who accepted offers this week. One last opening let's see who the lucky person will be! #winning!
Trading Spotlight
[http://www.mannkindcorp.com/Collateral/Documents/English-US/…[/url]
Unser CEO nimmt Stellung zur Dilution, er kämpft!
Unser CEO nimmt Stellung zur Dilution, er kämpft!
Ca. 12% Dilution...
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseI…
Wir haben durch den beschissenen Deal mit Sanofi extrem viel verloren - ich hoffe die ganzen Maßnahmen tragen dennoch irgendwann mal Früchte. Dauert natürlich alles extrem lange und geht nicht von heute auf morgen...
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseI…
Wir haben durch den beschissenen Deal mit Sanofi extrem viel verloren - ich hoffe die ganzen Maßnahmen tragen dennoch irgendwann mal Früchte. Dauert natürlich alles extrem lange und geht nicht von heute auf morgen...
Antwort auf Beitrag Nr.: 52.244.869 von Randfontein am 21.04.16 14:10:23lassen wir uns überraschen, was Mr. Pfeffer - hoffentlich wieder genesen - den Investoren am 26.04. von "epischer Tragweite" zu berichten weiß...
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseI…
http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseI…
Antwort auf Beitrag Nr.: 52.241.518 von tippse am 21.04.16 09:26:15Ich glaube nicht, daß das Mgmt "unfähig" ist. Eher sitzt es in einem tiefen Loch und muß erst mal mit viel Aufwand rauskrabbeln.
Ist ein wenig, wie ein Bundesligaverein, der zwangsweise in die Oberliga versetzt wurde und nun von vorn anfangen muß.
Bis MNKD angesichts der drohenden Verwässerung wieder Kurspotenzial nach oben hat, kann dauern.
Halte einen Wiedereinstieg für verfrüht, bleibt jedoch auf der Watchlist.
Jetzt erst recht! Wäre doch zu schön, wenn's mit Afrezza doch noch klappte.
Und dann wäre Technosphere plötzlich (wieder) eine ganz heiße Kiste!
Alles Gute!
Ist ein wenig, wie ein Bundesligaverein, der zwangsweise in die Oberliga versetzt wurde und nun von vorn anfangen muß.
Bis MNKD angesichts der drohenden Verwässerung wieder Kurspotenzial nach oben hat, kann dauern.
Halte einen Wiedereinstieg für verfrüht, bleibt jedoch auf der Watchlist.
Jetzt erst recht! Wäre doch zu schön, wenn's mit Afrezza doch noch klappte.
Und dann wäre Technosphere plötzlich (wieder) eine ganz heiße Kiste!
Alles Gute!
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
